<?xml version="1.0" encoding="UTF-8"?>
<p id="Par18">Tocilizumab injection is a recombinant humanized monoclonal antibody against human IL-6 receptor, which specifically binds to soluble and membranous IL-6 receptor to block signal transduction, thus inhibiting the activity of IL-6 receptor and achieving the goal of treating rheumatoid arthritis [
 <xref ref-type="bibr" rid="CR104">104</xref>â€“
 <xref ref-type="bibr" rid="CR106">106</xref>]. IL-6R plays an important role in the occurrence and development of some inflammatory and autoimmune diseases. As an activator of IL-6, sIL-6R can enhance the sensitivity of cells to IL-6 [
 <xref ref-type="bibr" rid="CR107">107</xref>]. It has been found that as an antagonist of cytokine interleukin-6 (IL-6), tocilizumab injection is likely to block cytokine storm and thus prevent COVID-19 patients from turning to severe and critical diseases [
 <xref ref-type="bibr" rid="CR108">108</xref>]. Tocilizumab injection has been recommended as a treatment for COVID-19 by researchers at University of Science and Technology of China.
</p>
